Imatinib Tablets 120 x 100mg(Imatinib Mesilate NK)

Reference priceKRW ₩850,500.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.

Brand	Imatinib
Manufacturer	Nihon Pharmaceutical Co.Ltd.
Prescription required	Yes

Description

Imatinib Tablets 120 x 100mg(Imatinib Mesilate NK) is a medicine catalog record in the MediPriceHub database. Active ingredient: Imatinib Mesilate. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Nihon Pharmaceutical Co.Ltd.. Therapeutic category: Medicine Library > Oncology Medicines > Gastrointestinal Stromal Tumors. Pack information: 100 / 120. Origin country or market: Japan. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.

Benefits

Imatinib mesylate is a kinase inhibitor indicated for the treatment of: • Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase • Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy • Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. • Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown • Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. • Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) • Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). • Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST.

How to Use

Use Imatinib Mesilate under the supervision of a qualified healthcare professional. Take it by mouth only according to the approved label and the dose prescribed by a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.

Specification

Active ingredient: Imatinib Mesilate. Pack size: 100 / 120. Pack unit: box. Manufacturer: Nihon Pharmaceutical Co.Ltd.. Origin country: Japan. Source category: Medicine Library > Oncology Medicines > Gastrointestinal Stromal Tumors. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.

Side Effects

Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.

이 정보는 참고용입니다. 의약품 사용 전 의료 전문가와 상담하세요.